Literature DB >> 23052559

[Behçet's disease].

I Kötter1, T Xenitidis, G Fierlbeck, S Schanz, A Melms, M Horger, U Ernemann, C Deuter.   

Abstract

Behçet's disease is a systemic disorder with the histopathological correlate of leukocytoclastic vasculitis. Pathogenetically, besides a strong genetic component participation of the innate immune system and an autoinflammatory component are discussed. The disease is most common in countries along the former silk route but in Germany the disease is rare (prevalence approximately 0.6/100,000). Oral aphthous ulcers are the main symptom, followed by skin manifestations, genital ulcers and oligoarthritis of large joints. Severe manifestations, threatening quality of life and even life itself, are the gastrointestinal manifestations which often perforate, arterial, mainly pulmonary arterial aneurysms which cause life-threatening bleeding, CNS manifestations and ocular disease, which with occlusive retinal vasculitis often leads to blindness. For milder manifestations low-dose steroids and colchicine are used, for moderate manifestations such as arthritis or ocular disease not immediately threatening visual acuity, azathioprin or cyclosporin A are combined with steroids. For severe manifestations, interferon-alpha, TNF-antagonists or cytotoxic drugs are recommended. Interleukin 1 (IL-1) antagonists are currently being examined in clinical studies.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23052559     DOI: 10.1007/s00393-012-1012-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  23 in total

Review 1.  Behçet's disease and thrombophilia.

Authors:  M Leiba; Y Sidi; H Gur; A Leiba; M Ehrenfeld
Journal:  Ann Rheum Dis       Date:  2001-12       Impact factor: 19.103

2.  Pulmonary artery aneurysms in Behçet syndrome.

Authors:  Vedat Hamuryudan; Tarik Er; Emire Seyahi; Canan Akman; Hasan Tüzün; Izzet Fresko; Sebahattin Yurdakul; Füruzan Numan; Hasan Yazici
Journal:  Am J Med       Date:  2004-12-01       Impact factor: 4.965

3.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

Review 4.  Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease.

Authors: 
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 5.  Associations between ankylosing spondylitis, psoriatic arthritis, Reiter's disease, the intestinal arthropathies, and Behcet's syndrome.

Authors:  J M Moll; I Haslock; I F Macrae; V Wright
Journal:  Medicine (Baltimore)       Date:  1974-09       Impact factor: 1.889

6.  Epidemiological features and visual prognosis of Behçet's disease.

Authors:  K Ando; Y Fujino; K Hijikata; Y Izawa; K Masuda
Journal:  Jpn J Ophthalmol       Date:  1999 Jul-Aug       Impact factor: 2.447

7.  Long-term remission after cessation of interferon-α treatment in patients with severe uveitis due to Behçet's disease.

Authors:  Christoph M E Deuter; Manfred Zierhut; Antje Möhle; Reinhard Vonthein; Nicole Stöbiger; Ina Kötter
Journal:  Arthritis Rheum       Date:  2010-09

Review 8.  The use of interferon alpha in Behçet disease: review of the literature.

Authors:  Ina Kötter; Ilhan Günaydin; Manfred Zierhut; Nicole Stübiger
Journal:  Semin Arthritis Rheum       Date:  2004-04       Impact factor: 5.532

9.  Increased enthesopathy among Behçet's syndrome patients with acne and arthritis: an ultrasonography study.

Authors:  Gulen Hatemi; Izzet Fresko; Koray Tascilar; Hasan Yazici
Journal:  Arthritis Rheum       Date:  2008-05

Review 10.  Hughes-Stovin syndrome.

Authors:  Umair Khalid; Taimur Saleem
Journal:  Orphanet J Rare Dis       Date:  2011-04-13       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.